The regulation of replication of ATL cells in SCID mouse

研究了抗亚洲苜蓿GM-1抗体（AAGM）治疗严重联合免疫缺陷（SCID）小鼠移植人T细胞白血病病毒i型（HTLV-I）感染的人T细胞的效果。当接种htlv - 1转化的人t细胞系MT-2时，接种部位形成不同大小肿瘤的频率在16/18（89%）的AAGM处理小鼠中显著高于16/26（62%）的AAGM未处理小鼠（p<0.05）。接种另一种HTLV-I转化的人t细胞系HUT102时，AAGM未处理小鼠的肿瘤形成率为7/10(70%)，与MT-2接近。AAGM治疗对肿瘤早期（小于3周）的发展有明显的促进作用，提示接种细胞后立即产生自然杀伤（NK）反应可能对预防肿瘤的发展起重要作用。肿瘤细胞的表面表型、克隆性等特征与MT-2细胞相同。23只接受AAGM治疗的小鼠接受了5例ATL患者的外周血单个核细胞，其中2只小鼠在注射部位出现肿瘤。此外，我们还观察到，将ATL患者和健康携带者的外周血淋巴细胞接种于AAGM治疗小鼠时，可通过聚合酶链反应检测到HTLV-I在各器官中的表达。这些结果清楚地表明，通过AAGM治疗消除NK功能是重要的，尽管在SCID小鼠中移植HTLV-I转化细胞并不总是必需的。

Effect of anti-asialo GM-1 antibody (AAGM) treatment on the graftment of severe combined immunodeficiency (SCID) mice with human T-cell leukemia virus type-I (HTLV-I) infected human T cells was studied. The frequency of forming tumors of various size at the inoculation site was significantly more in 16/18 (89%) of AAGM treated mice than in 16/26 (62%) of AAGM untreated mice (p<0.05), when an HTLV-I transformed human T-cell line, MT-2, was inoculated. When another HTLV-I transformed human T-cell line, HUT102, was inoculated, the frequency of forming tumors of was 7/10 (70%) in AAGM untreated mice, which was close to that of MT-2. The effect of AAGM treatment was obvious to promote the development of tumors in the early stage (less than 3 weeks), suggesting that an immediate natural killer (NK) reaction after inoculation of the cells might be important for the prevention of the tumor development. The characteristics of tumor cells, such as surface phenotypes and clonality, were same as those of MT-2 cells. Two of the 23 AAGM treated mice, which received peripheral blood mononuclear cells from 5 patients with ATL,developed tumors at the in jection site. In addition, it was observed that the HTLV-I could be detected in various organs by polymerase chain reaction, when the peripheral blood lymphocytes of ATL patients and of a healthy carrier were inoculated in AAGM treated mouse. These results clearly suggest that elimination of the NK function by AAGM treatment is important, although this is not always necessary for engrafting HTLV-I transformed cells in SCID mice.